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Summary 
‘Candidatus Mycoplasma turicensis’ (CMt) and ‘Mycoplasma haemofelis‘ (Mhf) are 
feline hemoplasmas that may induce anemia. Cats that overcome CMt infection 
demonstrate high antibody levels and are protected from a subsequent CMt challenge. 
In this study we aimed to investigate a possible cross protection between CMt and Mhf 
and characterize low-dose subcutaneous Mhf infection. Ten specified pathogen-free 
cats were exposed subcutaneously to 1’000 copies of Mhf: five cats were chronically 
infected with CMt (PCR-negative in blood but serologically positive, group A) and five 
cats served as naïve controls (group B). Bacterial loads were detected by real-time 
PCR. Hematology, clinical chemistry and serology were monitored. All ten cats became 
Mhf PCR-positive; cats in group A became significantly earlier Mhf PCR-positive and 
anemic and showed significant higher antibody levels than cats in group B. Mhf was 
demonstrated in saliva, rectal swabs and urine for the first time, although at low copy 
numbers. In conclusion, in contrast to the CMt-CMt-reinfection experiment, cats that 
recovered from CMt infection were not protected from a subsequent Mhf challenge. Our 
results may partly explain the diverse outcomes of Mhf infections observed in individual 
domestic cats. Furthermore, a small volume of Mhf infectious blood was sufficient for 
the induction of hemoplasmosis. We propose to use the low-dose challenge in future 
hemoplasma studies, which may more accurately mirror the natural way of 
transmission. 
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Zusammenfassung 
‘Candidatus Mycoplasma turicensis’ (CMt) und ‘Mycoplasma haemofelis‘ (Mhf) sind 
feline Hemoplasmen, die eine Anämie auslösen können. Katzen, die eine CMt-Infektion 
überstanden haben, weisen hohe Antikörpertiter auf, welche eine schützende Wirkung 
auf eine darauffolgende CMt-Infektion haben. Das Ziel unserer Studie war es, eine 
potentielle Kreuzimmunität zwischen CMt und Mhf aufzuzeigen, sowie die 
Charakterisierung der Infektion mit einem niedrig dosierten Mhf Inokulum. Zehn 
spezifisch pathogenfreie Katzen wurden subkutan mit 1'000 Mhf Kopien infiziert: Fünf 
der Katzen waren chronisch mit CMt infiziert (PCR-negativ, serologisch positiv, Gruppe 
A) und fünf naive Katzen dienten als Kontrolle (Gruppe B). Hämatologie, klinische 
Chemie, Serologie und real-time PCR dienten der Überwachung der Infektion. Katzen 
der Gruppe A wurden sowohl signifikant früher PCR-positiv, als auch anämisch und 
zeigten höhere Antikörpertiter als Katzen der Gruppe B. Zum ersten Mal konnte Mhf in 
Speichel- und Kottupfern, sowie im Urin nachgewiesen werden. Schlussfolgernd konnte 
aufgezeigt werden, dass Katzen, die sich von einer CMt-Infektion erholt haben, nicht vor 
einer darauffolgenden Mhf-Infektion geschützt sind. Desweiteren wurde festgestellt, 
dass eine Hämoplasmose bereits durch ein minimales Volumen von Mhf infiziertem Blut 
ausgelöst werden kann. Für zukünftige Hämoplasmen-Studien empfehlen wir deshalb 
die Benützung der niedrig dosierten Mhf-Inokula, um einen möglichst naturnahen Weg 
der Übertragung zu imitieren. 
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1. Introduction 
 
 
Hemotropic mycoplasmas (hemoplasmas) are cell-wall free bacteria, which can attach 
to red blood cells and may induce hemolytic anemia. Various mammalian species, 
including pets, as well as wild animals, can be infected with the bacteria. In the 
domestic cat three feline hemotropic mycoplasma species are known: ‘Mycoplasma 
haemofelis’ (Mhf), ‘Candidatus Mycoplasma haemominutum’ (CMhm) and ‘Candidatus 
Mycoplasma turicensis’ (CMt) [1-4]. Feline hemotropic mycoplasmas have been 
demonstrated worldwide with different prevalences [5-8]. The pathogenic potential 
significantly varies among the three feline species; Mhf seems to be the most 
pathogenic of the three species and an acute infection often results in hemolytic anemia 
[9, 10]. Clinical signs of a hemoplasmosis may include pallor, lethargy, anorexia, 
depression, dehydration and fever [10]. CMt was first isolated in 2005 in a Swiss pet cat 
[1]. Infection with CMt may result in a reduction of red blood cells (RBC) and hematocrit, 
but frequently no severe anemia was observed in CMt-infected cats. CMt-positive cats 
co-infected with CMhm or Mhf, in contrast, may show severe anemia [6].  
The route of transmission of feline hemoplasmas is still unknown, but arthropods such 
as fleas or ticks are suspected to play an important role [11-14]. Aggressive interactions 
between cats as well as blood transfusions have also been associated with 
transmission of hemotropic mycoplasma [15-17]. In experimental studies, the 
intraperitoneal and intravenous inoculation of large volumes of infectious blood was 
used to induce infection [9, 18-20]. However, these two routes of transmission seem to 
be a rather inadequate model for natural transmission. Results from a previous study 
with CMt [17] suggested that the subcutaneous inoculation and the use of small 
volumes of infectious blood, would mimic a more natural way of transmission of feline 
hemotropic mycoplasmas. So far, no data is available on low-dose Mhf infection. 
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The diagnosis of feline hemotropic mycoplasma infections relies on the detection and 
differentiation of the infectious agents by sensitive Polymerase Chain Reaction (PCR) 
assays [1, 21]. Furthermore, hemotropic mycoplasmas can be identified on stained 
blood smears, especially during high bacteremia. Hemoplasmas appear as small 
epicellular coccoid structures on the surface of the red blood cells [22]. To quantify the 
humoral immune response to feline hemoplasmas an enzyme-linked immunosorbent 
assay (ELISA) based on a recombinant Mhf DnaK protein was used [18, 23].   
The pathogenesis of hemotropic mycoplasma infections in cats is still poorly 
understood. Recently, it has been discovered, that cats previously exposed to CMt 
demonstrated high levels of antibodies even months after the initial bacteremia and that 
these cats were protected from a subsequent CMt challenge [24].  
The aims of the present study were to investigate subcutaneous low-dose Mhf infection 
and characterize the course of infection and the shedding pattern of Mhf. Furthermore 
we aimed to investigate a possible cross protection between CMt and the more 
pathogenic Mhf. 
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2. Materials and methods 
2.1. Animals and experimental design 
Ten adult male SPF cats (FIA1, FIA2, FHT1, FHX4, FHX5, KCY2, ZKA2, AKL4, JCT2, 
KCU1) were included in the present investigation. The cats were divided in two groups 
(groups A and B). Group A consisted of five cats (FIA1, FIA2, FHT1, FHX4, FHX5), 
which had previously undergone CMt infection [25]. After the cats had overcome the 
acute infection, they were PCR-negative for CMt, but serologically positive. All cats in 
group A were five years old at the time point of the start of the study. Group B consisted 
of five naïve cats (KCY2, ZKA2, AKL4, JCT2, KCU1). Three of the cats in group B 
(KCY2, JCT2, KCU1) were three years old; two cats (ZKA2, AKL4) were six years old at 
the beginning of the experiment. The ten cats were of blood type A. 
All animal experiments were performed according to the Swiss law and were officially 
approved by the veterinary office of the canton Zurich (TVB 159/2010). The cats were 
kept in two groups under etiologically and hygienically ideal conditions as described [26] 
and prior to the start of the study, the SPF status of the cats was verified, as described 
previously [17].  
All cats were challenged subcutaneously at day 0 with 1’000 copies of Mhf as 
determined by 16S rRNA TaqMan® real-time PCR. The way of inoculation and the dose 
of Mhf were chosen according to previous successful experimental CMt infections [17]. 
Infectious blood was diluted in a final volume of 100 µL (see below). EDTA-
anticoagulated blood and serum samples were collected for PCR analysis, hematology, 
clinical chemistry and serology from the ten cats before and regularly after the Mhf 
inoculation (Figures 1 and 2). Saliva and rectal swabs were collected regularly (time 
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points indicated in Figure 1) using commercially available cotton swabs (Primella, 
Migros Genossenschafts-Bund, Zurich, Switzerland) as described [13]. To look at the 
long-term shedding, we additionally tested the saliva and rectal swabs collected at days 
141, 232 and 286 post infection. Moreover, urine samples of all cats were collected by 
cystocentesis at three time points, one before and two after the Mhf inoculation (days  
-1, 57 and 104 post Mhf exposure). At the three time points, urinalysis was performed 
and the urine sediment was evaluated. Clinical condition, body temperature and body 
weight were recorded at each sampling time point. Cats were monitored for 371 days 
post Mhf exposure. Mhf-infected cats, which developed severe anemia (PCV < 10%) 
and/or were in a poor general condition were treated with doxycycline orally (10 
mg/kg/d, Grünenthal GmbH, Mitlödi, Switzerland) for 14 days, prednisolone orally (2 
mg/kg every 12h, gradually withdrawn, Streuli Pharma AG, Uznach, Switzerland) for ten 
days and fluid therapy (Ringer’s lactate solution, Fresenius Kabi (Schweiz) AG, Stans, 
Switzerland). 
2.2. Preparation of inoculum 
Heparinized infectious blood from cat QLA5 [18] preserved in dimethylsulfoxide (20%, 
vol/vol) in liquid nitrogen was used to prepare the inocula for the ten experimental cats. 
The blood contained 2.2 x 107 copies of Mhf/mL as determined by 16s rRNA TaqMan® 
real-time PCR. It was thawed at 37ºC and diluted in cold phosphate-buffered saline to a 
final concentration of 1 x 103 copies in 100 µL. The inoculum was kept on ice until use. 
Each cat was injected within five minutes of the preparation of the inoculum 
subcutaneously with 100 µL in the region of the neck. 
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2.3. Hematology and Coombs‘ test 
White blood cell differentials and complete hemograms were performed using a Sysmex 
XT-2000iV (Sysmex Corporation, Kobe, Japan) [27]. Packed Cell Volume (PCV) values 
between 33% and 45% were considered to be within the reference range as determined 
in our laboratory by using identical methods and blood samples from 63 clinically 
healthy cats; anemia was defined as a PCV value below 33%. In addition blood smears 
were prepared manually and were Giemsa stained using a Hema Tek 1000 (Bayer AG, 
Zurich, Switzerland). Blood smears were evaluated by light microscopy for Mhf. 
After the observation period of this study (371 days), the cats stayed in the facility under 
unchanged conditions. Coombs’ test was performed at different time points after the 
end of the observation time (at days 364, 387, 390 and 427 - 429 post Mhf exposure). 
Coombs’ testing was done as described previously [1], with the following modification: 
the feline anti-globulin Coombs’ reagent (ImmunO™, MP Biomedicals, Solon, Ohio) was 
serially diluted from 1:2 to 1:10’240. 
2.4. Clinical chemistry 
Serum chemistry was performed using a Cobas Integra 700 system (Roche 
Diagnostics, Rotkreuz, Switzerland) and included bilirubin, glucose, blood urea nitrogen 
(BUN), creatinine, protein, albumin, cholesterol, triglyceride, alkaline phosphatase, 
amylase, aspartate aminotransferase, alanine aminotransferase, lipase, sodium, 
chloride, potassium, calcium and phosphate. Reference ranges are stated as 5% and 
95% quantiles; they were determined in our laboratory using identical methods and 
blood samples from 59 clinically healthy cats. 
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2.5. Serum protein electrophoresis 
Serum protein electrophoresis was performed at selected time points before and after 
the Mhf infection (days -1, 44, 56, 58 and 69 post Mhf exposure). A semi-automated 
agarose gel electrophoresis system (Hydragel-Hydrasis, Sebia PN 4100, Issy-les 
Moulineaux, France) was used according to the procedure described by the 
manufacturer (Hydragel 7 Protein kit, Sebia PN 4100). Control serum (control serum P 
human, Sebia, Lysses, France) was included in each run. The relative protein 
concentration of each fraction was determined as the percentage optical absorbance, 
and the absolute concentration of each fraction (g/L) was calculated by multiplying the 
percentage with the total serum protein concentration. The reference ranges were 
determined in our laboratory using identical methods and serum samples from 59 
clinically healthy cats and are stated as 5% and 95% quantiles. 
2.6. Nucleic acids extractions 
Total nucleic acids (TNA) were extracted from 100 µL EDTA-anticoagulated blood using 
the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostic, Rotkreuz, 
Switzerland), as described previously [1]. The saliva and rectal swabs were incubated in 
phosphate-buffered saline at 40ºC for ten min prior to TNA extraction, as previously 
described [28]. TNA of urine samples were extracted from 100 µL urine using the 
MagNA Pure LC DNA Isolation Kit III (Bacteria, Fungi) (Roche Diagnostic, Rotkreuz, 
Switzerland). As pre-isolation steps, bacterial lysis buffer and proteinase K were added 
and the mixture was incubated at 65ºC for ten min. The subsequent procedure was 
according to the manufacturer’s instructions. 
TNA was eluted into 100 µL elution buffer and stored at -20ºC until PCR testing was 
performed. During all extractions, negative controls consisting of 100 µL phosphate-
buffered saline were concurrently prepared with each batch of samples to monitor for 
cross-contamination. 
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2.7. Quantitative TaqMan® real-time PCR assays 
All TNA samples were tested by TaqMan® real-time PCR for the presence and load of 
Mhf and CMt on an ABI PRISM 7700/7500 Sequence Detection System (Applied 
Biosystems, Rotkreuz, Switzerland), as previously described [1, 16]. All PCR runs were 
performed with positive and negative controls. 
2.8. Serology 
An ELISA based on a recombinant Mhf DnaK protein [18] was used in order to quantify 
the magnitude of the humoral immune response after Mhf exposure in the naïve cats 
and in the cats with preexisting anti-CMt-antibodies. The DnaK-ELISA was modified 
using a serum dilution of 1:500. The signal-to-noise ratio was calculated dividing the 
post- by the pre-infection absorbance values for each individual cat as described [18]. 
An ELISA signal ratio of ≥ 1.5 was considered serologically positive. Samples collected 
up to 371 days post Mhf exposure were included in the measurements. 
2.9.  Statistics 
Statistical analyses were performed using Graph-Pad Prism Version 3.0 (GraphPad 
Software, San Diego, CA, USA) and nonparametric tests. The parameters were 
compared between two groups using the Mann-Whitney U-test (PMWU). The Wilcoxon 
signed-rank test (PW) was used to compare the serum protein electrophoresis results 
from the same cat at two different time points. The Friedman’s test (PF), followed by the 
Dunn’s post test was used to analyze the parameters over time when more than two 
time points were considered. For the correlation analyses, the Spearman rank 
correlation test was used (PS). P values < 0.05 were considered to be significant. 
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3. Results 
3.1. Outcome of Mhf challenge and Mhf blood loads 
At the start of the study, the blood of all ten cats was Mhf- and CMt-negative as 
determined by TaqMan® real-time PCR. All cats turned Mhf PCR-positive during the 
experiment. CMt was never detectable by PCR in the blood of any of the cats. Among 
the cats in group A, cat FIA1 became Mhf PCR-positive at day nine, cats FHX4 and 
FHX5 at day 13 after the exposure and finally cats FIA2 and FHT1 became Mhf PCR-
positive at day 16 post exposure (Figure 1). KCY2 and AKL4 became PCR-positive at 
days 20 and 23 after the Mhf exposure, respectively; cats ZKA2 and KCU1 turned 
positive 27 and 30 days post exposure. The last cat to become PCR-positive was JCT2 
at day 34 after subcutaneous inoculation of Mhf. This was the only cat which showed 
some PCR-negative results unrelated to the antibiotic treatment (at days 37 and 41) 
within the first weeks after the cat had become PCR-positive. Moreover, this cat 
demonstrated the most severe outcome of the infection. Overall, cats in group A 
became Mhf PCR-positive within a range of 9 to 16 days post exposure, while cats in 
group B turned PCR-positive significantly later (in a range of 20 to 34 days post 
exposure, PMWU = 0.008). The maximum Mhf blood loads were comparable in both 
groups and reached ~109 copies/mL blood in each of the ten cats. Some marked copy 
number fluctuations were seen in the course of the Mhf infection in all cats, but 
particularly in a cat in group B, cat ZKA2. 
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Figure 1: Outcome of experimental subcutaneous Mhf exposure (at day 0) in ten SPF cats: five 
CMt-chronically infected cats (A-E), five naïve cats (F-J). Cat FIA1 (A), cat FIA2 (B), cat FHT1 
(C), cat FHX4 (D), cat FHX5 (E), cat KCY2 (F), cat ZKA2 (G), cat AKL4 (H), cat JCT2 (I) and cat 
KCU1 (J). The blood loads are presented as log DNA copy numbers per mL of blood (left y-axis) 
as determined by 16S rRNA TaqMan® real-time PCR and the PCV values are given as a 
percentage (right y-axis). The PCR results from saliva and rectal swabs are illustrated as 
triangles below the x-axes. PCR-positive swabs are demonstrated as filled symbols; PCR-
negative swabs are shown by open symbols. Only the first 90 days PI are shown. Cat JCT2 was 
treated as indicated with doxycycline (gray box marked “D”) and prednisolone (white box 
marked “P”). 
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Figure 2: Long-term follow-up of experimental subcutaneous Mhf exposure (at day 0) in ten 
SPF cats: five CMt-chronically infected cats (A-E), five naïve cats (F-J). For detailed cat 
identifications refer to Figure 1. The blood loads are presented as log DNA copy numbers per 
mL of blood (left y-axis) and the PCV values are given as percentage (right y-axis). 
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3.2. Clinical outcome 
Two cats in group A (FIA1, FIA2) and three cats in group B (KCY2, ZKA2, JCT2) 
showed transient clinical signs of hemoplasmosis, within the first nine weeks after 
subcutaneous inoculation of Mhf. Cats FIA1, FIA2, KCY2, ZKA2 were depressed, had 
pale mucous membranes and showed a reduced appetite over a period of a few days. 
No significant changes in body temperature or body weight were observed in any of the 
cats. 
At day 58 post Mhf exposure, cat JCT2 (group B) showed severe clinical signs like an 
enlarged abdomen (non-painful), pale mucous membranes, apathy, anorexia and an 
increased salivation. After evaluating the hematological parameters (PCV of 13%), the 
cat was treated with doxycycline and prednisolone as described in materials and 
methods. One week after the end of the doxycycline therapy, the cat turned PCR-
negative (Figure 1). In the subsequent week the cat became PCR-positive again; it 
showed a marked increase in Mhf copy numbers and reached 108 copies/mL of blood, 
the highest load measured in this cat. 
3.3. Hematology and Coombs’ test 
All cats in group A and four out of five cats in group B developed anemia (PCV < 33%) 
throughout the observation time (Figure 1). The cats in group A showed the onset of 
anemia 16 to 27 days post Mhf exposure and 7 to 14 days after the animals had turned 
PCR-positive. The PCV and RBC counts in cats in group A transiently decreased 
significantly at day 34, which corresponds to 18 to 25 days after the cats had turned 
PCR-positive (PCV PF < 0.0001; RBC < 7 x 10
6/µL, PF < 0.0001). In the four naïve cats 
in group B, which developed anemia, the onset of anemia was significantly later (34 to 
62 days post Mhf exposure and 11 to 35 days after becoming PCR-positive, PMWU = 
17 
 
0.03) than in the cats in group A. The PCV and RBC values in cats in group B 
transiently decreased at day 62, which relates to 28 to 42 days after the onset of PCR-
positivity (RBC PF = 0.04). The lowest PCV value was measured in cat JCT2 (group B) 
at day 58 post exposure (PCV = 13%).  
One month after the cats turned PCR-positive, a significant increase in monocytes (PF < 
0.0001) and a significant decrease in eosinophiles (PF < 0.0001) could be observed 
(Figure 3). No significant changes were found in total leucocyte, neutrophil and 
lymphocyte counts, when the hematological parameters were followed over time. In 
addition, no significant differences were found for total leucocyte and differential counts. 
Neutropenia (< 2.3 x 103/µL) was observed in several cats in both groups throughout 
the experiment, but particularly in cat JCT2 (group B). This cat showed severe 
neutropenia at different time points throughout the observation time. None of the cats 
showed any positive results in the Coombs’ test at the selected time points tested after 
the Mhf exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
0
2
4
6
8
10
12
0 50 100 150 200 250 300 350
Days post subcutaneous exposure
R
B
C
(1
0
6
/μ
L)
A
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 50 100 150 200 250 300 350
Days post subcutaneous exposure
M
o
n
o
cy
te
s 
(/
μ
L)
B
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 50 100 150 200 250 300 350
Days post subcutaneous exposure
C
Eo
si
n
o
p
h
ili
c 
 g
ra
n
u
lo
zy
te
s 
(/
μ
L)
0
2
4
6
8
10
12
0 50 100 150 200 250 300 350
Days post subcutaneous exposure
D
R
B
C
(1
06
/μ
L)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 50 100 150 200 250 300 350
Days post subcutaneous exposure
E
M
o
n
o
cy
te
s 
(/
μ
L)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 50 100 150 200 250 300 350
Days post subcutaneous exposure
F
Eo
si
n
o
p
h
ili
c 
 g
ra
n
u
lo
zy
te
s 
(/
μ
L)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Outcome of selected hematological parameters after experimental subcutaneous 
Mhf exposure (at day 0) in ten SPF cats: five CMt-chronically infected cats (A-C), five naïve 
cats (D-F). Median RBC (A, D), monocytes (B, E) and eosinophilic granulocytes (C, F) 
concentrations (y-axis) plotted against days post subcutaneous Mhf exposure. 
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3.4. Blood smears 
A selected sample of modified Wright stained blood smears, at time points during high 
bacteremia, was screened by light microscopy. Small epicellular coccoid structures 
could be identified on the surface of the red blood cells, they were found either 
individually, in pairs or as lined chains (Figure 4). Furthermore, anisocytosis, 
polychromatic erythrocytes and normoblasts were seen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Modified Wright stained blood smear from cat AKL4 (group B), 38 days after low-dose 
Mhf exposure. Small epicellular coccoid structures could be identified on the surface of the red 
blood cells (black arrows). Anisocytosis and polychromatic erythrocytes could also be identified 
compatible with regenerative anemia. 
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3.5. Clinical chemistry 
The cats showed significant changes in different clinical chemistry parameters during 
the observation time. One month after the cats in group A became PCR-positive, a 
significant increase in bilirubin (PF < 0.05) and total protein concentration (P < 0.01), as 
well as a significant decrease in albumin (PF < 0.001), cholesterol (PF < 0.01) and 
alkaline phosphatase (PF < 0.001) concentration could be observed (Figure 5).  
Cats in group B presented similar tendencies but not as pronounced as cats in group A. 
One month after becoming PCR-positive, the cats in group B had a significant increase 
in total protein concentration (PF < 0.01) and showed a significant decrease in albumin 
(PF < 0.001) and cholesterol (PF < 0.001). Glucose, blood urea nitrogen (BUN), 
creatinine, triglyceride, amylase, aspartate aminotransferase, alanine aminotransferase, 
lipase, sodium, chloride, potassium, calcium and phosphate blood levels did not show 
any significant changes. One cat in group B (JCT2) showed an increase in aspartate 
aminotransferase (108 U/l) and alanine aminotransferase (806 U/l) above the reference 
range at day 69 post exposure. 
 
 
 
 
 
 
Figure 5: Long-term follow-up of selected clinical chemistry parameters after experimental 
subcutaneous Mhf exposure (at day 0) in five CMt-chronically infected cats (A-E) and five naïve 
cats (F-J). Median bilirubin (A, F), total protein (B, G), albumin (C, H), cholesterol (D, I) and 
alkaline phosphatase (E, J) concentration (y-axis) plotted against days post subcutaneous Mhf 
exposure. 
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3.6. Serum protein electrophoresis 
Different changes in serum protein electrophoresis could be observed at selected time 
points (Figure 6). A significant decrease in albumin concentration (PW = 0.002) could be 
observed in all cats at day 58 after the Mhf exposure. Nine out of ten cats showed at 
least once during the observation time an albumin concentration below the reference 
range (<30-40 g/L). Simultaneously to this decrease in albumin, a significant increase in 
gamma globulines (PW = 0.002) could be found in all cats. Nine of the cats had gamma 
globuline concentrations above the reference range (up to 40.2 g/L; reference range 
5.7-16.0 g/L). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Representative serum protein electrophoresis of a cat (FIA1, group A) before the Mhf 
infection (A) and at day 44 post subcutaneous Mhf exposure (B). The electrophoretogram 
illustrates a polyclonal gammopathy at day 44 with a γ-globulin concentration of 40.2 g/L 
(reference range: 5.7 - 16.0 g/L). 
Albumin α 1 β γ α 2 
A 
Albumin α 1 α 2 β γ 
B 
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3.7. Mhf DNA shedding via saliva, feces and urine 
Saliva and rectal swabs were collected at the time points indicated in Figure 1 and at 
days 141, 232 and 286 post Mhf exposure. In all cats, some rectal swabs tested Mhf 
PCR-positive, while in only eight out of ten cats some saliva swabs were found positive. 
Two cats in group B (KCY2, KCU1) showed no PCR-positive saliva swabs during the 
whole observation time (Figure 1). The Mhf loads in saliva and feces were between 1 to 
26 copies/reaction, which calculated to 200 to 780 copies/swab. Most of the positive 
results were found during the time of high bacteremia. All saliva and rectal swabs 
collected at days 141, 232 and 286 post Mhf exposure tested Mhf PCR-negative. 
Urine samples were collected at three time points, pre- and post-infection. Mhf PCR-
positive results were found in eight out of ten cats post Mhf exposure. The Mhf loads in 
urine were between 1 to 699 copies/reaction, which calculated to 2 x 102 to 1.4 x 105 
copies/mL of urine. The highest Mhf level in urine was found in a sample with high 
erythrocyte contamination in urinalysis. 
3.8. Humoral immune response to Mhf 
The five naïve cats in group B were seronegative at the start of the study as determined 
by Mhf rDnaK ELISA (ELISA signal-to-noise ratio < 1.5; Figure 7). In these cats, the 
seroconversion took place seven to ten days after the cats became PCR-positive in the 
blood, except for cat JCT2, which seroconverted 21 days after PCR-positivity in blood 
(Figure 7B). The signal-to-noise ratio in this group reached a maximum of 17.6. The 
antibody levels increased after the peak Mhf blood loads and remained at a high level 
during the whole observation period for two cats (ZKA2, KCU1). For the three other cats 
in this group (KCY2, AKL4, JCT2) the level of antibodies decreased after reaching a 
peak (Figure 8B). The chronically infected cats (group A) were serologically positive 
(ELISA signal-to-noise ratio ≥ 1.5) at the beginning of this study (Figure 7A). In group A 
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an increase in antibody levels was observed three to ten days after the cats had 
become PCR-positive in blood. The signal-to-noise ratio in cats in group A reached a 
maximum of 30.3, which is significantly higher than the maximum in group B (PMWU = 
0.0079). Regarding the first 371 days post infection, the antibody levels were 
significantly correlated with the Mhf blood load (Spearmen correlation coefficient, r = 
0.41; PS < 0.0001). 
3.9. Long-term outcome of the infection 
Remarkably, five cats became PCR-negative in the blood for Mhf within the observation 
period without antibiotic treatment: four cats in group A and one cat in group B (Figure 
2). The remaining six cats were still PCR-positive at the end of this project, 371 days 
after Mhf exposure. 
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Figure 7:  Course of antibody response to Mhf after experimental subcutaneous Mhf exposure 
(at day 0) in ten SPF cats: five chronically infected cats (A), five naïve cats (B). The antibody 
levels are presented as ELISA signal-to-noise ratio determined using the Mhf rDnaK ELISA (y-
axis). An ELISA signal-to-noise ratio ≥1.5 (indicated by a dotted line) was defined to be positive 
[18]. 
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Figure 8:  Long-term follow-up of the antibody response to a Mhf infection after experimental 
subcutaneous Mhf exposure (at day 0) in ten SPF cats: five chronically infected cats (A), five 
naïve cats (B). The antibody levels are presented as ELISA signal-to-noise ratio determined 
using the Mhf rDnaK ELISA (y-axis). An ELISA signal-to-noise ratio ≥1.5 was defined to be 
positive [18]. 
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4. Discussion 
This is the first experimental study to show an infection with a low-dose Mhf inoculum 
and to monitor a possibly cross protection between CMt and the more pathogenic Mhf. 
In a previous transmission study [17] we demonstrated that subcutaneous inoculation of 
small volumes of infectious blood is sufficient to transmit a CMt infection and we 
speculated that this may mimic the natural way of transmission via arthropod vectors or 
aggressive interaction among cats. Arthropods like fleas or ticks are suspected to play 
an important role in the transmission of hemoplasmas [11-14]. Hemotropic 
mycoplasmas have been detected by TaqMan® real-time PCR in ticks and fleas 
collected from Swiss pet cats [12, 13]. Different studies evaluated risk factors for 
hemoplasma infection found old male cats with outdoor access more likely to be 
infected [16, 29]. The increased prevalence was explained by a higher frequency of 
aggressive contacts in the male cat population and the increased risk of exposure to 
arthropods in outdoor cats.  
We hypothesized that the minimal volume of blood transferred by arthropods or by 
aggressive contact may also be sufficient to transmit Mhf infection and provoke Mhf 
bacteremia. Thus, we decided to use a low-dose Mhf inoculum. In all previous 
experimental studies with Mhf, the intraperitoneal or intravenous inoculation of at least 
0.5 mL of Mhf PCR-positive blood was used to induce bacteremia [9, 18-20]. This is the 
first study demonstrating that a subcutaneous inoculation of 1’000 copies of Mhf 
corresponding to 0.05 µL of infectious blood with 107 copies/mL is sufficient to lead to a 
Mhf infection. All infected animals developed bacteremia and reached high blood loads 
(~109 copies/mL blood) comparable to reported high-dose experimental Mhf 
transmission studies [18-20]. However, cats infected subcutaneously with the low-dose 
inoculum turned PCR-positive later (9 to 34 days post exposure) than what had been 
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reported for cats inoculated intravenously or intraperitoneally [18, 19]. This fact may 
depend on the mechanisms by which Mhf reaches the blood stream after subcutaneous 
inoculation of infectious blood. We suspect that the bacteria were transported by the 
lymphatic system to finally arrive in the blood vessels. This mechanism is not 
completely clear, but may be a possible reason for the later appearance of PCR-positive 
results. Alternatively, the low-dose of the Mhf inoculum may have played a role in the 
delayed PCR-positivity. After inoculation, the organisms may have been present and 
even replicating in the blood; however the number of the bacteria may have been below 
the lower detection limit of the sensitive TaqMan® real-time PCR. Only when the blood 
loads reached a sufficient concentration (equal to what it would be after intraperitoneal 
or intravenous inoculation), organisms were detectable by PCR and the kinetics of the 
infection was similar to what had been reported before for the intraperitoneal or 
intravenous inoculation. According to our successful low-dose Mhf transmission results, 
especially veterinarians should be aware of a possible iatrogenic transmission of 
hemoplasma by minimal volumes of infectious blood, e.g. by multiple uses of needles 
(vaccination) or surgical materials (castration). 
The naïve cats (group B) seroconverted within seven days after the onset of PCR-
positivity, a duration that is similar to what had been described in previous studies [18, 
23]. Comparing the peak antibody levels between the two groups, significantly higher 
antibody titers were found in the chronically infected cats compared to the naïve cats. 
The CMt chronically infected cats showed a boost in antibody levels, three to ten days 
after turning PCR-positive. The level of antibodies found in the present study for Mhf 
infection was higher than the level of antibodies reported in CMt infection [24]. This may 
be due to the higher blood loads reached by Mhf compared to CMt. Furthermore, the 
higher antibody levels may be explained by the higher affinity of the Mhf antibodies to 
the antigen, which is based on the sequence of the Mhf DnaK protein [18]. 
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In a previous study, we had found that cats that underwent a CMt infection and 
recovered from CMt bacteremia subsequently were protected from a second CMt 
exposure [30]. If these cats were also protected from an infection with the more 
pathogenic Mhf, there would have been potential for Mhf vaccines based on the less 
harmful CMt. However, no protection against Mhf was found. In contrast, the chronically 
CMt-infected cats became PCR-positive significantly earlier than the naïve cats. 
Remarkably, no CMt was detectable at any time point in any of the cats. Had these cats 
been naturally infected and diagnostic PCR been run for Mhf and CMt, no difference 
would have been notable between cats in groups A and B (all just positive for Mhf), 
although they clearly show different infection kinetics. Thus, previous hemoplasma 
infections from which the cats have recovered may influence subsequent hemoplasma 
infections; this observation may contribute to the fact that natural hemoplasma 
infections may demonstrate differently in individual cats.  
There are several possible explanations for the unexpected finding that chronically CMt-
infected cats became significantly earlier PCR-positive than naïve cats. Pre-existing 
antibodies against hemoplasmas may have had an impact on the kinetic of the Mhf 
infection in cats that recovered from CMt infection. The reason behind this mechanism, 
the so-called antibody-dependent enhancement (ADE), is that the presence of specific 
antibodies against an infectious agent, can lead to an increased replication and 
distribution of the pathogen. ADE is particularly known in virus infections, e.g. feline 
infectious peritonitis virus, dengue virus, feline or human immunodeficiency virus [31-
34], but it has also been described in bacteria. The specific antibody response against 
Streptococcus pneumonia can enhance the adherence to and the colonization of 
respiratory cells [35, 36]. In our study, the chronically infected cats have antibodies 
against hemoplasmas prior to the Mhf exposure, as opposed to the naïve cats in group 
B. These antibodies may have bound to Mhf and the antibody-hemoplasma complex 
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may have been incorporated by phagocytic defense cells. This is based on the 
assumption that Mhf would be able to replicate and spread on a higher number from 
these cells. However, the replication of Mhf in/on cells other than erythrocytes has not 
been demonstrated [37]. For CMt and CMt reinfection no ADE has been found [30]. 
Alternatively, a modulation of the immune system may be responsible for the fact that 
chronically CMt infected cats turned Mhf PCR-positive earlier than the naïve cats. The 
influence of a hemotropic mycoplasma infection to the host immune system has not yet 
been completely elucidated. The humoral and the cellular immune system seem to play 
a role in the control of a hemoplasma infections [23, 24, 30, 38]. In a non-hemotropic 
mycoplasma infection, it has been reported that calves infected with Mycoplasma bovis 
showed a down-regulation of the immune system [39]. If chronically CMt-infected cats 
also undergo a down-regulation of the immune system, this may have led to a faster 
replication of Mhf and earlier PCR-positivity in the blood of cats in group A. Moreover, a 
modification or upregulation of potential hemoplasma binding receptors on the 
erythrocyte surface may also play a role in the binding of hemoplasma to the red blood 
cells. There has been evidence that patients with acute, severe hemoplasma infection 
had significantly elevated levels of complement receptors (CD35) compared to healthy 
controls [40]. Assuming that chronically infected cats had a similar up-regulation of 
potential hemoplasma receptors, they may have allowed for a more efficient binding of 
Mhf to the red blood cells and thus a faster replication. However, again, this was not 
found for CMt reinfection in chronically CMt-infected cats [30]. 
All cats reached high blood loads (~109 copies/mL), although the cats were infected with 
a low-dose Mhf inoculum. Apart from one cat, the high Mhf blood loads were associated 
by a marked decrease in PCV. While several cats showed only mild clinical signs of 
hemoplasmosis (depression, loss of appetite, pale mucous membranes), one cat (cat 
JCT2) developed severe anemia (PCV = 13%), which necessitated antibiotic treatment. 
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Thus, apart from the Mhf isolate, the inoculation route, dose and previously undergone 
hemoplasma infections, apparently additional individual factors may play a role in the 
susceptibility of different cats, e.g. the immune status or genetic background of the cat. 
An influence of the blood type, as previously postulated [17], can be excluded in the 
present study, because all cats were of blood type A.  
Some marked copy number fluctuations were observed during the course of Mhf 
infection also after the low-dose exposure – as has been reported after natural infection 
and high-dose infection [16, 18]. The fluctuation was especially pronounced in the early 
phase and in one cat in group B (ZKA2). This cat showed characteristic blood load 
cycling with three distinct Mhf load peaks between 23 and 48 days post infection. The 
fluctuations ranged from 104 to 108 copies/mL blood within a minimum of three days.  
Moreover, in accordance with natural and experimental high dose Mhf infections, Mhf 
was also detectable by light microscopy in the modified Wright stained blood smear 
prepared with blood collected during bacteremia. Mhf appeared as small coccoid 
structures on the surface of the red blood cells, as described [22]. Furthermore, 
anisocytosis, polychromatic erythrocytes and normoblasts were seen compatible with 
regenerative anemia. One month after the cats turned PCR-positive, a decrease in 
eosinophiles and simultaneously an increase in monocytes was observed. These 
changes are often associated with acute infections [41, 42]. 
Several changes in clinical chemistry were reported for the first time in feline 
hemoplasma infections. A significant increase in total protein concentration was 
observed one month after the cats had become PCR-positive. The increase in total 
protein was paralleled by a decrease in albumin, which may be explained by the role of 
albumin as negative acute phase protein [43]. Different factors like dehydration, liver 
and kidney disease have an influence on the level of proteins [43]. In the present study, 
the increase in total protein concentration during hemoplasma infection may be mainly 
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attributed to an increased production of immunoglobulins. This assumption was 
supported by the hypergammaglobulinemia detected in the serum protein 
electrophoresis in nine out of ten cats. Furthermore a decrease in alkaline phosphatase 
and cholesterol was seen during the observation time. Considering that the half-life of 
alkaline phosphatase in cats is very short, it is difficult to interpret these values. The Mhf 
infection may lead to a general increase of the metabolic activity, which may result in an 
additional decrease of the half-life of alkaline phosphatase. Cholesterol plays an 
important role in the construction of cell membranes and the production of hormones 
and bile acid. Alterations in the lipid metabolism and decreased cholesterol levels have 
been reported in a many infections, including viral, bacterial and parasitic infections [44, 
45]. The observed decrease in cholesterol concentration in the present study may be 
due to an increased need of cholesterol for membrane synthesis for either large 
numbers of RBCs that have been destroyed during the Mhf infection and/or – what 
seems more probable – the fast amplification of hemoplasmas. It has been shown that 
mycoplasmas depend on the host to provide cholesterol for the synthesis of their 
membranes [39]. Due to their small genome, they have limited metabolic options for 
survival and replication and depend on exogenous substrates [46, 47]. In addition, they 
incorporate large quantities of cholesterol into their membrane for improved membrane 
fluidity [39]. High levels of cholesterol have been shown to enhance replication of some 
bacteria and cholesterol catabolism may be a therapeutic target against these infections 
[45]. Moreover, a significant increase in bilirubin concentration was observed. As 
described earlier [10], an acute Mhf infection may lead to hemolytic anemia, which may 
result in a rise of bilirubin concentration. In addition, cat JCT2 showed an increased 
ASAT (108 U/l) and ALAT (806 U/l) at day 69 post infection; these elevations could be 
explained by the foregoing treatment with doxycycline. Cats in group B showed similar 
tendencies in clinical chemistry, but as a group not as pronounced as cats in group A. 
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This may be due to fact that the time points of PCR conversion in the naïve cats was 
spread more widely over time compared to the chronically infected cats. The changes 
observed in clinical chemistry and the serum protein electrophoresis were not high 
enough to potentially aid establish an accurate diagnosis but they add new insights into 
the infection pathogenesis. 
Finally, the shedding patterns of Mhf were investigated. The present study reports for 
the first time, that Mhf DNA was shed by saliva, feces and urine. Positive saliva and 
rectal swabs could be found particularly during high bacteremia. However, all Mhf-
positive swabs showed a low hemoplasma load, comparable to the loads demonstrated 
for CMt [13, 17]. The saliva and rectal swabs collected at later time points, > 100 days 
post inoculation, were all negative. So far there have been no Mhf transmission studies 
using PCR-positive saliva or feces. For CMt, it has been demonstrated that PCR-
positive saliva does not pose a significant risk of infection transmission, when inoculated 
either orally or subcutaneously [17]. In addition, Mhf PCR-positive urine samples were 
found in the present study. The urine samples were collected by cystocentesis; 
therefore a contamination with erythrocytes cannot be completely excluded. However, 
Mhf PCR-positive results were also detected in urine samples, where no erythrocytes 
were detected by urinalysis and in the urine sediment. The low Mhf copy numbers in 
saliva, feces and urine of Mhf-infected cats are indicative for a low risk of transmission 
by sharing of feeding dishes, toys or cat toilets by Mhf PCR-positive and -negative cats. 
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5.  Conclusion 
 
 
In conclusion, we demonstrated that cats that had recovered from CMt infection were 
not protected against a subsequent Mhf challenge. In contrast, they became PCR-
positive and anemic significantly earlier than the naïve cats. Our study demonstrated 
that a minimal contact to Mhf infectious blood was sufficient for the transmission of the 
infection and induction of hemoplasmosis. Thus, we propose to use the low-dose 
challenge in future hemoplasma studies to reflect the natural way of transmission. 
Moreover, we demonstrated for the first time that Mhf is shed by saliva, feces and urine 
especially during the time of high bacteremia. In addition, it was found that 
approximately half of the Mhf-infected cats may become PCR-negative even in the 
absence of antibiotic treatment as had been reported for most CMt-infected cats, while 
others stayed Mhf PCR-positive in the blood for more than a year after Mhf infection, 
similar to what was mostly seen for CMhm.  
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